In a letter posted to the FDA’s website and dated Monday, the pharma said there is “limited supply” and an “impending stock out situation” for prefilled Bicillin L-A and Bicillin C-R syringes, which are also used to treat pneumonia, strep throat and other bacterial infections. To alleviate the possible shortage, Pfizer said it’s prioritizing the production of Bicillin L-A prefilled syringes, according to a Pfizer spokesperson.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters